Prosecution Insights
Last updated: November 13, 2026

Omniseq Inc.

Technology areas: Biotechnology & Pharmaceuticals • Transportation, E-Commerce & Mechanical Systems

2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days

Analysis

Omniseq Inc. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 2 distinct examiners and 2 distinct art units, showing that current prosecution is divided across separate examination assignments. This distribution calls for coordinated portfolio oversight, but the response to each action should remain tied to its own examiner and art-unit context.

SALMON, KATHERINE D is the busiest examiner, with 1 pending matter. No examiner accounts for all of the identified pending activity, so counsel should not assume that one response strategy will govern the portfolio. Reviewing the actions together may reveal common biotechnology themes, while separate prosecution records remain necessary.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

2
Total Pending OAs
0
Non-Final OAs
2
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

0
Overdue
0
Due this week
0
Due this month
1
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

2
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 + other2 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
50% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
1
Mechanical / Eng
50% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

20 h
Manual time on pending OAs
4 h
Time saved (low, 20%)
7 h
Time saved (mid, 35%)
0.2 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
SALMON, KATHERINE D 1 42.7% +38.2%
WHALEY, PABLO S 1 25.0% +21.4%

Hard Cases (2)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18055292 Methods and Systems for Analyzing and Utilizing Cancer Testis Antigen Burden SALMON, KATHERINE D 55d
17452873 METHODS AND SYSTEMS FOR CHARACTERIZING TUMOR RESPONSE TO IMMUNOTHERAPY USING AN IMMUNOGENIC PROFILE WHALEY, PABLO S —

Interview Candidates (2)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18055292 Methods and Systems for Analyzing and Utilizing Cancer Testis Antigen Burden SALMON, KATHERINE D 55d
17452873 METHODS AND SYSTEMS FOR CHARACTERIZING TUMOR RESPONSE TO IMMUNOTHERAPY USING AN IMMUNOGENIC PROFILE WHALEY, PABLO S —

Top Art Units

Art UnitApps
1682 1
3619 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18055292 Methods and Systems for Analyzing and Utilizing Cancer Testis Antigen Burden SALMON, KATHERINE D 1682 §101§103§112Other Final Rejection 55d Pending Nov 14, 2022
17452873 METHODS AND SYSTEMS FOR CHARACTERIZING TUMOR RESPONSE TO IMMUNOTHERAPY USING AN IMMUNOGENIC PROFILE WHALEY, PABLO S 3619 §101§103§112 Final Rejection — Pending Oct 29, 2021

Managing Omniseq Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Omniseq Inc. have?

Omniseq Inc. has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.

Which USPTO examiner handles the most Omniseq Inc. applications?

Katherine D Salmon has the most, with 1 of Omniseq Inc.'s pending office actions.

What technology area are Omniseq Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month